Dataset Information

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

ABSTRACT: After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

SUBMITTER: Berry S

PROVIDER: S-EPMC6373015 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry Sneha S Giraldo Nicolas N Nguyen Peter P Green Benjamin B Xu Haiying H Ogurtsova Aleksandra A Soni Abha A Succaria Farah F Wang Daphne D Roberts Charles C Stein Julie J Engle Elizabeth E Pardoll Drew D Anders Robert R Cottrell Tricia T Taube Janis M JM Tran Ben B Voskoboynik Mark M Kuo James J Bang Yung-Lue YL Chung Hyun-Cheo HC Ahn Myung-Ju MJ Kim Sang-We SW Perera Ayesh A Freeman Daniel D Achour Ikbel I Faggioni Raffaella R Xiao Feng F Ferte Charles C Lemech Charlotte C Meric-Bernstam Funda F Werner Theresa T Hodi Stephen S Messersmith Wells W Lewis Nancy N Talluto Craig C Dostalek Mirek M Tao Aiyang A McWhirter Sarah S Trujillo Damian D Luke Jason J Xu Chunxiao C BoMarelli Qi Jin J Qin Guozhong G Yu Huakui H Jenkins Molly M Lo Kin-Ming KM Halle Joern-Peter JP Lan Yan Y Taylor Matthew M Vogelzang Nicholas N Cohn Allen A Stepan Daniel D Shumaker Robert R Dutcus Corina C Guo Matthew M Schmidt Emmett E Rasco Drew D Brose Marcia M Vogelzang Nicholas N Di Simone Christopher C Jain Sharad S Richards Donald D Encarnacion Carlos C Rasco Drew D Shumaker Robert R Dutcus Corina C Stepan Daniel D Guo Matthew M Schmidt Emmett E Taylor Matthew M Vogelzang Nicholas N Encarnacion Carlos C Cohn Allen A Di Simone Christopher C Rasco Drew D Richards Donald D Taylor Matthew M Dutcus Corina C Stepan Daniel D Shumaker Robert R Guo Matthew M Schmidt Emmett E Mier James J An Jeongshin J Yang Yeun-Yeoul YY Lee Won-Hee WH Yang Jinho J Kim Jong-Kyu JK Kim Hyun Goo HG Paek Se Hyun SH Lee Jun Woo JW Woo Joohyun J Kim Jong Bin JB Kwon Hyungju H Lim Woosung W Paik Nam Sun NS Kim Yoon-Keun YK Moon Byung-In BI Janku Filip F Tan David D Martin-Liberal Juan J Takahashi Shunji S Geva Ravit R Gucalp Ayca A Chen Xueying X Subramanian Kulandayan K Mataraza Jennifer J Wheler Jennifer J Bedard Philippe P

Journal for immunotherapy of cancer 20190213 1

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction. ...[more]

PMID: 30760319

Similar Datasets

Project description:Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinations in the clinic may still face formidable challenges in regulatory, drug-availability and intellectual property aspects. The 2011 SITC annual meeting hosted a workshop on combination immunotherapy to discuss: 1) the most promising combinations found in the laboratory; 2) early success of combination immunotherapy in clinical trials; 3) industry perspectives on combination approaches, and 4) relevant regulatory issues. The integrated theme was how to accelerate the implementation of efficacious combined immunotherapies for cancer patients. Rodent animal models are providing many examples of synergistic combinations that typically include more than two agents. However, mouse and human immunology differ in a significant number of mechanisms and hence we might be missing opportunities peculiar to humans. Nonetheless, incisive animal experimentation with deep mechanistic insight remains the best compass that we can use to guide our paths in combinatorial immunotherapy. Combination immunotherapy clinical trials are already in progress and preliminary results are extremely promising. As a key to translate promising combinations into clinic, real and "perceived" business and regulatory hurdles were debated. A formidable step forward would be to be able to test combinations of investigational agents prior to individual approval. Taking together the FDA and the industrial perspective on combinatorial immunotherapy, the audience was left with the clear message that this is by no means an impossible task. The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace.

Dataset Information

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Publications

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets